SCHEMBL6125

SCHEMBL6125

CC(C)Oc1ccc(N2CC[C@]3(CC[C@](O)(C4CCCC4)CC3)C2)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR4 Q5NUL3 4/20 0.41
ALDH1A1 P00352 6/20 0.40
USP2 O75604 5/20 0.40
KMT2A Q03164 3/20 0.40
HSD17B10 Q99714 3/20 0.40
MAPT P10636 2/20 0.40
ALOX15 P16050 2/20 0.40
SMN1; SMN2 Q16637 3/20 0.39
KDM4E B2RXH2 2/20 0.39
ACACB O00763 4/20 0.37
CYP3A4 P08684 5/20 0.36
CYP2C9 P11712 4/20 0.36
MAPK1 P28482 3/20 0.36
MEN1 O00255 2/20 0.36
CYP2C19 P33261 2/20 0.36
CYP1A2 P05177 3/20 0.36
HIF1A Q16665 3/20 0.36
OPRM1 P35372 1/20 0.36
OPRD1 P41143 1/20 0.36
OPRK1 P41145 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5569 0.82 USP2 (0.41) FFAR4ALDH1A1USP2KMT2AHSD17B10
SCHEMBL5546 0.78 LIPE (0.44) FFAR4ALDH1A1USP2KMT2AHSD17B10
SCHEMBL12701943 0.75 LIPE (0.61) LIPE
SCHEMBL10066 0.75 LIPE (0.61) LIPE
SCHEMBL10065 0.75 LIPE (0.61) LIPE
SCHEMBL5081 0.74 SIGMAR1 (0.41) FFAR4ALDH1A1USP2KMT2AHSD17B10
SCHEMBL10819 0.70 LIPE (0.61) LIPE
SCHEMBL10820 0.70 LIPE (0.61) LIPE
SCHEMBL12701882 0.70 LIPE (0.61) LIPE
SCHEMBL20000542 0.67 MAPT (0.66) ALDH1A1USP2KMT2AHSD17B10MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2488493-A1 SPIRO-CONDENSED CYCLOHEXANE DERIVATIVES AS HSL INHIBITORS USEFUL FOR THE TREATMENT OF DIABETES F. Hoffmann-La Roche AG (CH) 2012-08-22 EP claimed
WO-2011045292-A1 SPIRO-CONDENSED CYCLOHEXANE DERIVATIVES AS HSL INHIBITORS USEFUL FOR THE TREATMENT OF DIABETES F. HOFFMANN-LA ROCHE AG (CH) 2011-04-21 WO claimed